Day: April 2, 2024

Mutual Trust Bank launches biometric cards with IDEX Biometrics in Bangladesh

Written by Customer Service on April 2, 2024. Posted in Public Companies.

Oslo, Norway and Dhaka, Bangladesh – 02 April 2024: Mutual Trust Bank Limited (MTB) in Bangladesh is launching biometric payment cards based on IDEX Pay, the biometric solution from IDEX Biometrics. Mutual Trust Bank ranks amongst the top ten banks in Bangladesh and is recognized as one of the most sustainable banks of Bangladesh, winning Bangladesh’s best bank for diversity and inclusion award in 20231. MTB is known for bringing innovative solutions to market in a customer-centric way, with their digital banking approach largely contributing to Bangladesh’s economic growth, offering financial support and inclusion for all. Biometric payment cards, equipped with fingerprint sensors, offers unparalleled security by uniquely linking the cardholder’s identity to each transaction. “Contactless biometric payment cards align...

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

Written by Customer Service on April 2, 2024. Posted in Public Companies.

COPENHAGEN, Denmark, April 2, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S., marking a significant expansion for access to JYNNEOS® by establishing additional pathways for vaccine procurement, distribution, and reimbursement by both public and private payers. Since 2022, in response to the global mpox outbreak, JYNNEOS has been made available through public health channels for individuals at risk of mpox infection. This was made possible through Bavarian Nordic’s long-standing partnership with the U.S. government to supply the vaccine for the national stockpile and enabled by interim guidance from the Centers for Disease Control and Prevention (CDC), recommending pre- and post-exposure use of the vaccine for individuals at risk during...

Cnova N.V. : Acquisition of Predominant Control over Cnova

Written by Customer Service on April 2, 2024. Posted in Public Companies.

Financial Restructuring of Casino Group Results in Change of Control over Cnova AMSTERDAM – April 2, 2024, 08:15 CET Cnova N.V. (Euronext Paris: CNV; ISIN: NL0010949392) (“Cnova”) hereby informs as follows: On behalf of France Retail Holdings S.à.r.l. (an entity ultimately controlled by Mr. Daniel Křetínský) (“FRH”), it is hereby announced that pursuant to the completion of the financial restructuring of the Casino group on March 27, 2024 (https://www.groupe-casino.fr/en/announcements/), FRH has acquired indirectly (via Casino Guichard-Perrachon S.A.) 99.27% of the voting rights in Cnova, thus acquiring predominant control (overwegende zeggenschap) over Cnova. FRH is a special purpose vehicle set up by a consortium consisting of EP Equity Investment III S.à.r.l. (“EP”), Fimalac and Attestor, and is controlled by...

Voting Rights and Denominator

Written by Customer Service on April 2, 2024. Posted in Public Companies.

Press ReleaseRegulated InformationAntwerp, 2 April 2024– 7.00 a.m. CET In application of Article 15 of the Law of May 2, 2007 on the disclosure of major shareholdings in issuers whose shares are admitted for trading on a regulated market, VGP publishes, by means of a press release and on its website, the total share capital, the total number of securities with voting rights and the total number of voting rights at the latest at the end of each month in which any of these numbers has changed. Situation as at 31 March 2024:Total share capital: € 136,091,705.08Total number of securities with voting right: 27,291,312Total number of securities with double voting right: 12,406,540Total number of voting rights (= denominator): 39,697,852This situation (the denominator) serves as a basis for the notification of major shareholdings...

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Written by Customer Service on April 2, 2024. Posted in Public Companies.

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) targetSTRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies1PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003. STRO-003, an antibody-drug conjugate (ADC) in the final stages of pre-clinical development, targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including...

Corbion and Kingswood Capital Management announce the completion of the divestiture of the emulsifier business

Written by Customer Service on April 2, 2024. Posted in Mergers And Acquisitions.

Corbion, a leading global ingredient solutions provider, and Kingswood Capital Management, LP (“Kingswood”), a middle-market private equity firm with significant experience in corporate carve-outs have completed the earlier announced sale of Corbion’s emulsifiers business. Based in Los Angeles, Kingswood acquired the emulsifier business from Corbion for a cash purchase price of $362M, with expected net cash proceeds of approximately $275M, post tax and transaction costs. The transaction comprises, amongst other conveying assets, two US-based manufacturing plants and c.175 employees. Corbion and Kingswood will work together, with supply and service agreements in place, to enable a smooth transition and to ensure that customers continue to experience a high level of service. “Kingswood is excited to take this world-class Emulsifiers...

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Written by Customer Service on April 2, 2024. Posted in Public Companies.

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibitor — HONG KONG, SHANGHAI, China & FLORHAM PARK, N.J., April 02, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:1801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 or non-MSI-H2 tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation has been accepted and granted priority review by the China National Medical Products...

PyroGenesis Announces 2023 Fourth Quarter and Year End Results

Written by Customer Service on April 2, 2024. Posted in Earnings Releases And Operating Results.

MONTREAL, April 01, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce its financial and operational results for the fourth quarter and the fiscal year ended December 31st, 2023. “2023 was an interesting year for PyroGenesis, as we dealt with many of the issues associated with the growth and adoption of clean technology in a cautious economic environment,” said P. Peter Pascali, President and CEO of PyroGenesis. “We navigated cash management challenges brought about by higher costs associated with commercializing...

BlueRush Releases Fiscal Q2 2024 Results

Written by Customer Service on April 2, 2024. Posted in Earnings Releases And Operating Results.

BlueRush continues to close gap on profitability while adding significant new customers in the quarter TORONTO, April 01, 2024 (GLOBE NEWSWIRE) — BlueRush Inc. (“BlueRush” or the “Company“) ‎‎‎(TSXV:BTV; OTCQB:BTVRF), ‎a personalized video Software as a Service (“SaaS“) company, today announced its financial results for the three and six months ended January 31, 2024. “BlueRush has been executing a plan that has included a significant reduction in expenses while recalibrating our sales approach around our new platform capabilities and the opportunities these represent,” said Steve Taylor, CEO of BlueRush. Strategic and financial highlights:Overall operating expenses reduced by $312,577 or 23% compared to Q2 2023 The Company signed 8 new logo customers in the quarter The Company also signed...

Fluent, Inc. to Announce Fourth Quarter and Full-Year 2023 Financial Results on April 2, 2024

Written by Customer Service on April 2, 2024. Posted in Public Companies.

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT) announced today that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2023, after the close of the U.S. financial markets on April 2, 2024. Fluent will host a conference call at 4:30 pm ET on the same day to discuss the results. The conference call can be accessed by phone after registering online at Fluent Conference Call or via audio at Audio Registration. The call will also be webcast simultaneously on the Fluent website on the Investor Relations Page. Please log in at least 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be required. Following the call, a recorded replay of the webcast will be available for one year on Fluent’s Investor Relations Page. About Fluent,...

Day: April 2, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice